aluates Reports

$ 0.0

Automative

Global HR+HER2- Breast Cancer Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-15K5976

Global HR HER2 Breast Cancer Market Insights and Forecast to 2028

BUY CHAPTERS

Global HR+HER2- Breast Cancer Market Research Report 2025

Code: QYRE-Auto-15K5976

Report

September 2025

Pages:83

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Jiangsu Hengrui Medicine

Odonate Therapeutics

Radius Pharmaceuticals

Immunomedics

Roche Group

Syndax Pharmaceuticals

Merck

Eagle Pharmaceuticals

Merrimack Pharmaceuticals

GlaxoSmithKline PLC

Millennium Pharmaceuticals

Bayer

HR+HER2- Breast Cancer Market

The global market for HR+HER2- Breast Cancer was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

HR+/HER2-Breast Cancer

North American market for HR+HER2- Breast Cancer is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for HR+HER2- Breast Cancer is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for HR+HER2- Breast Cancer in Hospitals is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of HR+HER2- Breast Cancer include Jiangsu HengRui Medicine, Odonate Therapeutics, Radius Pharmaceuticals, Immunomedics, Roche Group, Syndax Pharmaceuticals, Merck, Eagle Pharmaceuticals, Merrimack Pharmaceuticals, GlaxoSmithKline, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for HR+HER2- Breast Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HR+HER2- Breast Cancer.

The HR+HER2- Breast Cancer market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global HR+HER2- Breast Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the HR+HER2- Breast Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of HR+HER2- Breast Cancer Market Report

Report Metric	Details
Report Name	HR+HER2- Breast Cancer Market
Segment by Type	CDK4/6 Inhibitors PARP Inhibitors PI3K Inhibitor Others
Segment by Application	Hospitals Cancer Center Medical Research and Academic Institutions Ambulatory Surgical Centers Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Jiangsu HengRui Medicine, Odonate Therapeutics, Radius Pharmaceuticals, Immunomedics, Roche Group, Syndax Pharmaceuticals, Merck, Eagle Pharmaceuticals, Merrimack Pharmaceuticals, GlaxoSmithKline, Millennium Pharmaceuticals, Bayer
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of HR+HER2- Breast Cancer company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the HR+HER2- Breast Cancer Market report?

Ans: The main players in the HR+HER2- Breast Cancer Market are Jiangsu HengRui Medicine, Odonate Therapeutics, Radius Pharmaceuticals, Immunomedics, Roche Group, Syndax Pharmaceuticals, Merck, Eagle Pharmaceuticals, Merrimack Pharmaceuticals, GlaxoSmithKline, Millennium Pharmaceuticals, Bayer

What are the Application segmentation covered in the HR+HER2- Breast Cancer Market report?

Ans: The Applications covered in the HR+HER2- Breast Cancer Market report are Hospitals, Cancer Center, Medical Research and Academic Institutions, Ambulatory Surgical Centers, Others

What are the Type segmentation covered in the HR+HER2- Breast Cancer Market report?

Ans: The Types covered in the HR+HER2- Breast Cancer Market report are CDK4/6 Inhibitors, PARP Inhibitors, PI3K Inhibitor, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global HR+HER2- Breast Cancer Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 CDK4/6 Inhibitors

1.2.3 PARP Inhibitors

1.2.4 PI3K Inhibitor

1.2.5 Others

1.3 Market by Application

1.3.1 Global HR+HER2- Breast Cancer Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospitals

1.3.3 Cancer Center

1.3.4 Medical Research and Academic Institutions

1.3.5 Ambulatory Surgical Centers

1.3.6 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global HR+HER2- Breast Cancer Market Perspective (2020-2031)

2.2 Global HR+HER2- Breast Cancer Growth Trends by Region

2.2.1 Global HR+HER2- Breast Cancer Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 HR+HER2- Breast Cancer Historic Market Size by Region (2020-2025)

2.2.3 HR+HER2- Breast Cancer Forecasted Market Size by Region (2026-2031)

2.3 HR+HER2- Breast Cancer Market Dynamics

2.3.1 HR+HER2- Breast Cancer Industry Trends

2.3.2 HR+HER2- Breast Cancer Market Drivers

2.3.3 HR+HER2- Breast Cancer Market Challenges

2.3.4 HR+HER2- Breast Cancer Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top HR+HER2- Breast Cancer Players by Revenue

3.1.1 Global Top HR+HER2- Breast Cancer Players by Revenue (2020-2025)

3.1.2 Global HR+HER2- Breast Cancer Revenue Market Share by Players (2020-2025)

3.2 Global HR+HER2- Breast Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by HR+HER2- Breast Cancer Revenue

3.4 Global HR+HER2- Breast Cancer Market Concentration Ratio

3.4.1 Global HR+HER2- Breast Cancer Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by HR+HER2- Breast Cancer Revenue in 2024

3.5 Global Key Players of HR+HER2- Breast Cancer Head office and Area Served

3.6 Global Key Players of HR+HER2- Breast Cancer, Product and Application

3.7 Global Key Players of HR+HER2- Breast Cancer, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 HR+HER2- Breast Cancer Breakdown Data by Type

4.1 Global HR+HER2- Breast Cancer Historic Market Size by Type (2020-2025)

4.2 Global HR+HER2- Breast Cancer Forecasted Market Size by Type (2026-2031)

5 HR+HER2- Breast Cancer Breakdown Data by Application

5.1 Global HR+HER2- Breast Cancer Historic Market Size by Application (2020-2025)

5.2 Global HR+HER2- Breast Cancer Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America HR+HER2- Breast Cancer Market Size (2020-2031)

6.2 North America HR+HER2- Breast Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America HR+HER2- Breast Cancer Market Size by Country (2020-2025)

6.4 North America HR+HER2- Breast Cancer Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe HR+HER2- Breast Cancer Market Size (2020-2031)

7.2 Europe HR+HER2- Breast Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe HR+HER2- Breast Cancer Market Size by Country (2020-2025)

7.4 Europe HR+HER2- Breast Cancer Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific HR+HER2- Breast Cancer Market Size (2020-2031)

8.2 Asia-Pacific HR+HER2- Breast Cancer Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific HR+HER2- Breast Cancer Market Size by Region (2020-2025)

8.4 Asia-Pacific HR+HER2- Breast Cancer Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America HR+HER2- Breast Cancer Market Size (2020-2031)

9.2 Latin America HR+HER2- Breast Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America HR+HER2- Breast Cancer Market Size by Country (2020-2025)

9.4 Latin America HR+HER2- Breast Cancer Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa HR+HER2- Breast Cancer Market Size (2020-2031)

10.2 Middle East & Africa HR+HER2- Breast Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa HR+HER2- Breast Cancer Market Size by Country (2020-2025)

10.4 Middle East & Africa HR+HER2- Breast Cancer Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Jiangsu HengRui Medicine

11.1.1 Jiangsu HengRui Medicine Company Details

11.1.2 Jiangsu HengRui Medicine Business Overview

11.1.3 Jiangsu HengRui Medicine HR+HER2- Breast Cancer Introduction

11.1.4 Jiangsu HengRui Medicine Revenue in HR+HER2- Breast Cancer Business (2020-2025)

11.1.5 Jiangsu HengRui Medicine Recent Development

11.2 Odonate Therapeutics

11.2.1 Odonate Therapeutics Company Details

11.2.2 Odonate Therapeutics Business Overview

11.2.3 Odonate Therapeutics HR+HER2- Breast Cancer Introduction

11.2.4 Odonate Therapeutics Revenue in HR+HER2- Breast Cancer Business (2020-2025)

11.2.5 Odonate Therapeutics Recent Development

11.3 Radius Pharmaceuticals

11.3.1 Radius Pharmaceuticals Company Details

11.3.2 Radius Pharmaceuticals Business Overview

11.3.3 Radius Pharmaceuticals HR+HER2- Breast Cancer Introduction

11.3.4 Radius Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2020-2025)

11.3.5 Radius Pharmaceuticals Recent Development

11.4 Immunomedics

11.4.1 Immunomedics Company Details

11.4.2 Immunomedics Business Overview

11.4.3 Immunomedics HR+HER2- Breast Cancer Introduction

11.4.4 Immunomedics Revenue in HR+HER2- Breast Cancer Business (2020-2025)

11.4.5 Immunomedics Recent Development

11.5 Roche Group

11.5.1 Roche Group Company Details

11.5.2 Roche Group Business Overview

11.5.3 Roche Group HR+HER2- Breast Cancer Introduction

11.5.4 Roche Group Revenue in HR+HER2- Breast Cancer Business (2020-2025)

11.5.5 Roche Group Recent Development

11.6 Syndax Pharmaceuticals

11.6.1 Syndax Pharmaceuticals Company Details

11.6.2 Syndax Pharmaceuticals Business Overview

11.6.3 Syndax Pharmaceuticals HR+HER2- Breast Cancer Introduction

11.6.4 Syndax Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2020-2025)

11.6.5 Syndax Pharmaceuticals Recent Development

11.7 Merck

11.7.1 Merck Company Details

11.7.2 Merck Business Overview

11.7.3 Merck HR+HER2- Breast Cancer Introduction

11.7.4 Merck Revenue in HR+HER2- Breast Cancer Business (2020-2025)

11.7.5 Merck Recent Development

11.8 Eagle Pharmaceuticals

11.8.1 Eagle Pharmaceuticals Company Details

11.8.2 Eagle Pharmaceuticals Business Overview

11.8.3 Eagle Pharmaceuticals HR+HER2- Breast Cancer Introduction

11.8.4 Eagle Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2020-2025)

11.8.5 Eagle Pharmaceuticals Recent Development

11.9 Merrimack Pharmaceuticals

11.9.1 Merrimack Pharmaceuticals Company Details

11.9.2 Merrimack Pharmaceuticals Business Overview

11.9.3 Merrimack Pharmaceuticals HR+HER2- Breast Cancer Introduction

11.9.4 Merrimack Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2020-2025)

11.9.5 Merrimack Pharmaceuticals Recent Development

11.10 GlaxoSmithKline

11.10.1 GlaxoSmithKline Company Details

11.10.2 GlaxoSmithKline Business Overview

11.10.3 GlaxoSmithKline HR+HER2- Breast Cancer Introduction

11.10.4 GlaxoSmithKline Revenue in HR+HER2- Breast Cancer Business (2020-2025)

11.10.5 GlaxoSmithKline Recent Development

11.11 Millennium Pharmaceuticals

11.11.1 Millennium Pharmaceuticals Company Details

11.11.2 Millennium Pharmaceuticals Business Overview

11.11.3 Millennium Pharmaceuticals HR+HER2- Breast Cancer Introduction

11.11.4 Millennium Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2020-2025)

11.11.5 Millennium Pharmaceuticals Recent Development

11.12 Bayer

11.12.1 Bayer Company Details

11.12.2 Bayer Business Overview

11.12.3 Bayer HR+HER2- Breast Cancer Introduction

11.12.4 Bayer Revenue in HR+HER2- Breast Cancer Business (2020-2025)

11.12.5 Bayer Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Jiangsu Hengrui Medicine

Odonate Therapeutics

Radius Pharmaceuticals

Immunomedics

Roche Group

Syndax Pharmaceuticals

Merck

Eagle Pharmaceuticals

Merrimack Pharmaceuticals

GlaxoSmithKline PLC

Millennium Pharmaceuticals

Bayer

List of Tables

Table 1. Global HR+HER2- Breast Cancer Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of CDK4/6 Inhibitors

Table 3. Key Players of PARP Inhibitors

Table 4. Key Players of PI3K Inhibitor

Table 5. Key Players of Others

Table 6. Global HR+HER2- Breast Cancer Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global HR+HER2- Breast Cancer Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global HR+HER2- Breast Cancer Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global HR+HER2- Breast Cancer Market Share by Region (2020-2025)

Table 10. Global HR+HER2- Breast Cancer Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global HR+HER2- Breast Cancer Market Share by Region (2026-2031)

Table 12. HR+HER2- Breast Cancer Market Trends

Table 13. HR+HER2- Breast Cancer Market Drivers

Table 14. HR+HER2- Breast Cancer Market Challenges

Table 15. HR+HER2- Breast Cancer Market Restraints

Table 16. Global HR+HER2- Breast Cancer Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global HR+HER2- Breast Cancer Market Share by Players (2020-2025)

Table 18. Global Top HR+HER2- Breast Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HR+HER2- Breast Cancer as of 2024)

Table 19. Ranking of Global Top HR+HER2- Breast Cancer Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by HR+HER2- Breast Cancer Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of HR+HER2- Breast Cancer, Headquarters and Area Served

Table 22. Global Key Players of HR+HER2- Breast Cancer, Product and Application

Table 23. Global Key Players of HR+HER2- Breast Cancer, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global HR+HER2- Breast Cancer Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global HR+HER2- Breast Cancer Revenue Market Share by Type (2020-2025)

Table 27. Global HR+HER2- Breast Cancer Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global HR+HER2- Breast Cancer Revenue Market Share by Type (2026-2031)

Table 29. Global HR+HER2- Breast Cancer Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global HR+HER2- Breast Cancer Revenue Market Share by Application (2020-2025)

Table 31. Global HR+HER2- Breast Cancer Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global HR+HER2- Breast Cancer Revenue Market Share by Application (2026-2031)

Table 33. North America HR+HER2- Breast Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America HR+HER2- Breast Cancer Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America HR+HER2- Breast Cancer Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe HR+HER2- Breast Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe HR+HER2- Breast Cancer Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe HR+HER2- Breast Cancer Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific HR+HER2- Breast Cancer Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific HR+HER2- Breast Cancer Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific HR+HER2- Breast Cancer Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America HR+HER2- Breast Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America HR+HER2- Breast Cancer Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America HR+HER2- Breast Cancer Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa HR+HER2- Breast Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa HR+HER2- Breast Cancer Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa HR+HER2- Breast Cancer Market Size by Country (2026-2031) & (US$ Million)

Table 48. Jiangsu HengRui Medicine Company Details

Table 49. Jiangsu HengRui Medicine Business Overview

Table 50. Jiangsu HengRui Medicine HR+HER2- Breast Cancer Product

Table 51. Jiangsu HengRui Medicine Revenue in HR+HER2- Breast Cancer Business (2020-2025) & (US$ Million)

Table 52. Jiangsu HengRui Medicine Recent Development

Table 53. Odonate Therapeutics Company Details

Table 54. Odonate Therapeutics Business Overview

Table 55. Odonate Therapeutics HR+HER2- Breast Cancer Product

Table 56. Odonate Therapeutics Revenue in HR+HER2- Breast Cancer Business (2020-2025) & (US$ Million)

Table 57. Odonate Therapeutics Recent Development

Table 58. Radius Pharmaceuticals Company Details

Table 59. Radius Pharmaceuticals Business Overview

Table 60. Radius Pharmaceuticals HR+HER2- Breast Cancer Product

Table 61. Radius Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2020-2025) & (US$ Million)

Table 62. Radius Pharmaceuticals Recent Development

Table 63. Immunomedics Company Details

Table 64. Immunomedics Business Overview

Table 65. Immunomedics HR+HER2- Breast Cancer Product

Table 66. Immunomedics Revenue in HR+HER2- Breast Cancer Business (2020-2025) & (US$ Million)

Table 67. Immunomedics Recent Development

Table 68. Roche Group Company Details

Table 69. Roche Group Business Overview

Table 70. Roche Group HR+HER2- Breast Cancer Product

Table 71. Roche Group Revenue in HR+HER2- Breast Cancer Business (2020-2025) & (US$ Million)

Table 72. Roche Group Recent Development

Table 73. Syndax Pharmaceuticals Company Details

Table 74. Syndax Pharmaceuticals Business Overview

Table 75. Syndax Pharmaceuticals HR+HER2- Breast Cancer Product

Table 76. Syndax Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2020-2025) & (US$ Million)

Table 77. Syndax Pharmaceuticals Recent Development

Table 78. Merck Company Details

Table 79. Merck Business Overview

Table 80. Merck HR+HER2- Breast Cancer Product

Table 81. Merck Revenue in HR+HER2- Breast Cancer Business (2020-2025) & (US$ Million)

Table 82. Merck Recent Development

Table 83. Eagle Pharmaceuticals Company Details

Table 84. Eagle Pharmaceuticals Business Overview

Table 85. Eagle Pharmaceuticals HR+HER2- Breast Cancer Product

Table 86. Eagle Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2020-2025) & (US$ Million)

Table 87. Eagle Pharmaceuticals Recent Development

Table 88. Merrimack Pharmaceuticals Company Details

Table 89. Merrimack Pharmaceuticals Business Overview

Table 90. Merrimack Pharmaceuticals HR+HER2- Breast Cancer Product

Table 91. Merrimack Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2020-2025) & (US$ Million)

Table 92. Merrimack Pharmaceuticals Recent Development

Table 93. GlaxoSmithKline Company Details

Table 94. GlaxoSmithKline Business Overview

Table 95. GlaxoSmithKline HR+HER2- Breast Cancer Product

Table 96. GlaxoSmithKline Revenue in HR+HER2- Breast Cancer Business (2020-2025) & (US$ Million)

Table 97. GlaxoSmithKline Recent Development

Table 98. Millennium Pharmaceuticals Company Details

Table 99. Millennium Pharmaceuticals Business Overview

Table 100. Millennium Pharmaceuticals HR+HER2- Breast Cancer Product

Table 101. Millennium Pharmaceuticals Revenue in HR+HER2- Breast Cancer Business (2020-2025) & (US$ Million)

Table 102. Millennium Pharmaceuticals Recent Development

Table 103. Bayer Company Details

Table 104. Bayer Business Overview

Table 105. Bayer HR+HER2- Breast Cancer Product

Table 106. Bayer Revenue in HR+HER2- Breast Cancer Business (2020-2025) & (US$ Million)

Table 107. Bayer Recent Development

Table 108. Research Programs/Design for This Report

Table 109. Key Data Information from Secondary Sources

Table 110. Key Data Information from Primary Sources

Table 111. Authors List of This Report

List of Figures

Figure 1. HR+HER2- Breast Cancer Picture

Figure 2. Global HR+HER2- Breast Cancer Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global HR+HER2- Breast Cancer Market Share by Type: 2024 VS 2031

Figure 4. CDK4/6 Inhibitors Features

Figure 5. PARP Inhibitors Features

Figure 6. PI3K Inhibitor Features

Figure 7. Others Features

Figure 8. Global HR+HER2- Breast Cancer Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global HR+HER2- Breast Cancer Market Share by Application: 2024 VS 2031

Figure 10. Hospitals Case Studies

Figure 11. Cancer Center Case Studies

Figure 12. Medical Research and Academic Institutions Case Studies

Figure 13. Ambulatory Surgical Centers Case Studies

Figure 14. Others Case Studies

Figure 15. HR+HER2- Breast Cancer Report Years Considered

Figure 16. Global HR+HER2- Breast Cancer Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 17. Global HR+HER2- Breast Cancer Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 18. Global HR+HER2- Breast Cancer Market Share by Region: 2024 VS 2031

Figure 19. Global HR+HER2- Breast Cancer Market Share by Players in 2024

Figure 20. Global Top HR+HER2- Breast Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HR+HER2- Breast Cancer as of 2024)

Figure 21. The Top 10 and 5 Players Market Share by HR+HER2- Breast Cancer Revenue in 2024

Figure 22. North America HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. North America HR+HER2- Breast Cancer Market Share by Country (2020-2031)

Figure 24. United States HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Canada HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Europe HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Europe HR+HER2- Breast Cancer Market Share by Country (2020-2031)

Figure 28. Germany HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. France HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. U.K. HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Italy HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Russia HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Nordic Countries HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Asia-Pacific HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Asia-Pacific HR+HER2- Breast Cancer Market Share by Region (2020-2031)

Figure 36. China HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Japan HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. South Korea HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Southeast Asia HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. India HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Australia HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Latin America HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Latin America HR+HER2- Breast Cancer Market Share by Country (2020-2031)

Figure 44. Mexico HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Brazil HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Middle East & Africa HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Middle East & Africa HR+HER2- Breast Cancer Market Share by Country (2020-2031)

Figure 48. Turkey HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Saudi Arabia HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. UAE HR+HER2- Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. Jiangsu HengRui Medicine Revenue Growth Rate in HR+HER2- Breast Cancer Business (2020-2025)

Figure 52. Odonate Therapeutics Revenue Growth Rate in HR+HER2- Breast Cancer Business (2020-2025)

Figure 53. Radius Pharmaceuticals Revenue Growth Rate in HR+HER2- Breast Cancer Business (2020-2025)

Figure 54. Immunomedics Revenue Growth Rate in HR+HER2- Breast Cancer Business (2020-2025)

Figure 55. Roche Group Revenue Growth Rate in HR+HER2- Breast Cancer Business (2020-2025)

Figure 56. Syndax Pharmaceuticals Revenue Growth Rate in HR+HER2- Breast Cancer Business (2020-2025)

Figure 57. Merck Revenue Growth Rate in HR+HER2- Breast Cancer Business (2020-2025)

Figure 58. Eagle Pharmaceuticals Revenue Growth Rate in HR+HER2- Breast Cancer Business (2020-2025)

Figure 59. Merrimack Pharmaceuticals Revenue Growth Rate in HR+HER2- Breast Cancer Business (2020-2025)

Figure 60. GlaxoSmithKline Revenue Growth Rate in HR+HER2- Breast Cancer Business (2020-2025)

Figure 61. Millennium Pharmaceuticals Revenue Growth Rate in HR+HER2- Breast Cancer Business (2020-2025)

Figure 62. Bayer Revenue Growth Rate in HR+HER2- Breast Cancer Business (2020-2025)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Women s Health Care Drugs Market Research Report 2024

Global HER2 Human Epidermal Growth Factor Receptor 2 Inhibitors Market Research Report 2024

Global Drug Delivery in Cancer Market Insights Forecast to 2030

Global Cancer Immunotherapy Drug Discovery Outsourcing Market Insights Forecast to 2030

Global Breast Lesion Localization Market Insights Forecast to 2030

Global Estradiol Test Kit Market Research Report 2024

Global Menopause Test Kits Market Research Report 2024

Global Health Information Systems HIS Market Insights Forecast to 2030

Global Women s Jewelry Market Research Report 2024

Global HER 2 Targeted Drugs for Breast Cancer Market Research Report 2024

Global HER2 Positive Breast Cancer Market Research Report 2024

Global Vitamins and Supplements for Women Market Research Report 2024

Global Cancer Janus Kinase Inhibitors Market Research Report 2024

Global Human Resource Software Market Insights Forecast to 2030

Global Women Safety Software Market Insights Forecast to 2030

Global Metastatic Colorectal Cancer Drug Market Insights Forecast to 2030

HER2 Testing Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Health Service Provider Services Market Research Report 2024

HER 2 Negative Breast Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5L19798

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28I6901

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22R9736

Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29A2598

Tue Sep 09 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions